ASCENDIS PHARMA A/S's ticker is ASND and the CUSIP is 04351P101. A total of 171 filers reported holding ASCENDIS PHARMA A/S in Q4 2021. The put-call ratio across all filers is 1.59 and the average weighting 0.8%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $22,661 | +182.1% | 242 | +168.9% | 0.00% | +100.0% |
Q2 2023 | $8,033 | +24.9% | 90 | +50.0% | 0.00% | 0.0% |
Q1 2023 | $6,433 | +50.5% | 60 | +71.4% | 0.00% | 0.0% |
Q4 2022 | $4,275 | +6.9% | 35 | 0.0% | 0.00% | 0.0% |
Q3 2022 | $4,000 | +300.0% | 35 | +250.0% | 0.00% | – |
Q4 2021 | $1,000 | – | 10 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Vivo Capital, LLC | 1,797,745 | $265,886,000 | 19.06% |
RA Capital Management | 4,914,955 | $726,922,000 | 14.16% |
Sofinnova Investments, Inc. | 1,109,874 | $164,150,000 | 10.35% |
Eventide Asset Management | 1,709,848 | $252,887,000 | 5.50% |
Asymmetry Capital Management, L.P. | 47,599 | $7,040,000 | 5.39% |
BERYLSON CAPITAL PARTNERS, LLC | 58,200 | $8,608,000 | 5.30% |
Avoro Capital Advisors LLC | 1,750,000 | $258,825,000 | 5.12% |
Eversept Partners, LP | 220,344 | $32,588,878 | 4.47% |
Spyglass Capital Management LLC | 452,104 | $66,866,000 | 4.14% |
Orbimed Advisors | 1,562,986 | $231,166,000 | 3.25% |